OpenResearchAlpha

bioRxiv · 17 Nov 2026

Elucidating the Sodium Channel-Targeting Anti-Seizure Medication Interactome: A Drug-Target Pathway Analysis

Srinivasan Ekambaramh-index 14, Erika T. Axeen, Jaideep Kapur, Howard P Goodkin, Nikolay V. Dokholyanh-index 77

0
Citations
no database records one yet
0
Citations in 2026
so far
77
Leading author's h-index
Nikolay V. Dokholyan, in QAI's scholar index
0
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Epilepsy is a common neurological disorder in both children and adults, primarily managed with anti-seizure medications (ASMs). Sodium channel blockers are among the most commonly used ASMs. These medications exhibit distinct spectra of efficacy and side effect profiles. These likely result from different off-target interactions, protein binding profiles, and subunit selectivity that remain poorly characterized. We developed a neural network-based computational pipeline to systematically elucidate the molecular targets and associated biological pathways of selected sodium channel-modulating ASMs: carbamazepine, lamotrigine, eslicarbazepine, licarbazepine, lacosamide, phenytoin, and cenobamate. Using the DRIFT (Drug-target identification based on chemical similarity) algorithm for proteome-wide target prediction, we identified protein targets for these ASMs. The sodium channel alpha subunit family was the highest-ranked target for every drug except cenobamate, for which it ranked second behind the GABA-A receptor. Pathway mapping in the Reactome database revealed both shared and drug-specific biological processes. Furthermore, molecular docking studies elucidated the atomistic interactions between the drugs and the predicted targets. Specifically, the predicted target landscape varied from eslicarbazepine and licarbazepine (59 predicted targets each) to lacosamide (18). Pathway analysis revealed recurrent enrichment in rapid depolarisation and the interaction between L1 and ankyrins shared across all drugs, alongside predicted off-targets, including the cannabinoid CB1 receptor for phenytoin and the carbonic anhydrases for lacosamide. Molecular docking supported these predictions, with binding scores ranging from -24 to -31 kcal/mol. Overall, this work provides a systems-level view of NaV-targeting ASM pharmacology and a hypothesis-generating framework to prioritize mechanistic and combination studies of these medications in epilepsy.

Neuroscience

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • Nikolay V. Dokholyan has the highest h-index among the authors (77).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (5)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (0)

What it cites, from open citation data, with Crossref's record of each.

No references in the open citation data yet.